Supercede Therapeutics Inc. has released preclinical efficacy data on its small-molecule inhibitor of the Activin receptor type II (ACTRII) to treat obesity.

At the 11th Congress of the European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers ...

Given that there is no confirmed CDC director and a small newly appointed panel with many members lacking a broad vaccine or immunology knowledge, “there are concerns about the rushed nature of this ...

Abion Inc. signed a potential $1.315 billion deal with an anonymous partner June 22, granting the counterparty exclusive ...

Abbott Laboratories grabbed attention in early June with its announcement of a partnership with Tandem Diabetes Care Inc. to develop a multianalyte sensor for people with diabetes that would measure ...

With a growing number of people wearing continuous glucose monitors and an ever-shrinking number of hospital-based nurses, ...

Xlear Inc., of Salt Lake City filed a petition in U.S. district court that could terminate the Federal Trade Commission’s ...

Cue Biopharma Inc. has received pre-IND feedback from the FDA to discuss the proposed development plan for CUE-401, its lead ...

Ophthalmology company Polyactiva Pty Ltd closed a AU$40 million (US$25 million) series C round to advance late-stage clinical trials in the U.S. of its lead candidate, PA-5108.

Australia’s largest health insurance company, Medibank Private Ltd., is the first to reimburse for psychedelic treatment in Australia, funding Emyria Ltd.’s MDMA (3,4-methylenedioxy-methamphetamine) ...

The U.K. government will soon unveil its 10-year health plan to transform the National Health Service. The aim is to tackle the problems in the 76-year-old system and make it fit for the future. The ...

Kymera Therapeutics Inc. found itself juggling partnerships by bringing one on board while going to the development bench in another. Kymera and Gilead Sciences Inc. will collaborate on a molecular ...